Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?
- PMID: 26078469
- DOI: 10.1093/annonc/mdv246
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?
Comment on
-
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701454 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical